Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03600805

Recruitment Status : Terminated (Protracted recruitment timeline exacerbated by COVID-19 pandemic)

First Posted : July 26, 2018

Results First Posted : January 14, 2022

Last Update Posted : March 28, 2022

View this study on Beta.ClinicalTrials.gov

Sponsor:

Collaborator:

Regeneron Pharmaceuticals

Information provided by (Responsible Party):

Sanofi

Study Description

Brief Summary:

Primary Objective:

To evaluate the efficacy of sarilumab in participants with giant cell arteritis (GCA) as assessed by the proportion of participants with sustained remission for sarilumab compared to placebo, in combination with a corticosteroid (CS) tapering course.

Secondary Objective:

To demonstrate the efficacy of sarilumab in participants with GCA compared to placebo, in combination with CS taper with regards to:
Clinical responses (such as responses based on disease remission rates, time to first disease flare) over time.
Cumulative CS (including prednisone) exposure.
To assess the safety (including immunogenicity) and tolerability of sarilumab in participants with GCA.
To measure sarilumab serum concentrations in participants with GCA.
To assess the effect of sarilumab on sparing glucocorticoid toxicity as measured by glucocorticoid toxicity index (GTI).

Condition or disease	Intervention/treatment	Phase
Giant Cell Arteritis	Drug: Sarilumab SAR153191 Drug: Sarilumab matching placebo Drug: Prednisone Drug: Prednisone matching placebo	Phase 3

Detailed Description:

Study duration per participant was approximately 82 weeks, including an up to 6-week screening period, 52-week treatment period, and 24-week follow-up period.

Study Design

Layout table for study information

Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	83 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:	Treatment
Official Title:	A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Sarilumab in Patients With Giant Cell Arteritis
Actual Study Start Date :	November 20, 2018
Actual Primary Completion Date :	November 24, 2020
Actual Study Completion Date :	November 24, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Giant Cell Arteritis Polymyalgia Rheumatica Steroids

Drug Information available for: Sarilumab

Genetic and Rare Diseases Information Center resources: Giant Cell Arteritis

U.S. FDA Resources

Arms and Interventions

Arm	Intervention/treatment
Experimental: Placebo+52 Week Taper Participants received sarilumab-matching placebo as subcutaneous (SC) injection every 2 weeks (q2w) up to 52 weeks along with the combination of prednisone and/or prednisone-matching placebo according to the protocol-defined schedule. Participants received prednisone/prednisone-matching placebo tapering oral daily doses for 52 weeks.	Drug: Sarilumab matching placebo Pharmaceutical form: solution for injection Route of administration: subcutaneous Drug: Prednisone Pharmaceutical form: tablets or capsules Route of administration: oral administration Drug: Prednisone matching placebo Pharmaceutical form: capsules Route of administration: oral administration
Experimental: Placebo+26 Week Taper Participants received sarilumab-matching placebo as SC injection q2w up to 52 weeks along with the combination of prednisone and/or prednisone-matching placebo according to the protocol-defined schedule. Participants received prednisone tapering oral daily doses during the first 26 weeks and prednisone-matching placebo from Week 26 up to Week 52.	Drug: Sarilumab matching placebo Pharmaceutical form: solution for injection Route of administration: subcutaneous Drug: Prednisone Pharmaceutical form: tablets or capsules Route of administration: oral administration Drug: Prednisone matching placebo Pharmaceutical form: capsules Route of administration: oral administration
Placebo Comparator: Sarilumab 150mg q2w+26 Week Taper Participants received sarilumab 150 milligrams (mg) as SC injection q2w up to 52 weeks along with prednisone and/or prednisone-matching placebo according to the protocol-defined schedule. Participants received prednisone tapering oral daily doses during the first 26 weeks and prednisone-matching placebo from Week 26 up to Week 52.	Drug: Sarilumab SAR153191 Pharmaceutical form: solution for injection Route of administration: subcutaneous Drug: Prednisone Pharmaceutical form: tablets or capsules Route of administration: oral administration Drug: Prednisone matching placebo Pharmaceutical form: capsules Route of administration: oral administration
Placebo Comparator: Sarilumab 200mg q2w+26 Week Taper Participants received sarilumab 200 mg as SC injection q2w up to 52 weeks along with prednisone and/or prednisone-matching placebo according to the protocol-defined schedule. Participants received prednisone tapering oral daily doses during the first 26 weeks and prednisone-matching placebo from Week 26 up to Week 52.	Drug: Sarilumab SAR153191 Pharmaceutical form: solution for injection Route of administration: subcutaneous Drug: Prednisone Pharmaceutical form: tablets or capsules Route of administration: oral administration Drug: Prednisone matching placebo Pharmaceutical form: capsules Route of administration: oral administration

Outcome Measures

Primary Outcome Measures :

Percentage of Participants Who Achieved Sustained Disease Remission at Week 52 [ Time Frame: At Week 52 ]
Disease remission was defined as resolution of signs and symptoms of giant cell arteries (GCA), and normalization of C-reactive protein (CRP) (<10 mg/L). Sustained remission was defined as meeting all of the following parameters: achievement of disease remission not later than Week 12, absence of disease flare (defined as recurrence of signs and symptoms attributable to active GCA plus an increase in corticosteroid [CS] dose due to GCA or elevation of erythrocyte sedimentation rate [ESR] attributable to active GCA plus an increase in CS dose due to GCA) from Week 12 through Week 52, normalization of CRP (to <10 mg/L, with absence of successive elevations to >=10 mg/L) from Week 12 through Week 52, and successful adherence to prednisone taper from Week 12 through Week 52.
Percentage of Participants Who Achieved Sustained Disease Remission at Week 24 [ Time Frame: At Week 24 ]
Disease remission was defined as resolution of signs and symptoms of GCA, and normalization of CRP <10 mg/L. Sustained remission was defined as meeting all of the following parameters: achievement of disease remission not later than Week 12, absence of disease flare (defined as recurrence of signs and symptoms attributable to active GCA plus an increase in CS dose due to GCA, or elevation of ESR attributable to active GCA plus an increase in CS dose due to GCA) from Week 12 through Week 24, normalization of CRP (to <10 mg/L, with an absence of successive elevations to >=10 mg/L) from Week 12 through Week 24, and successful adherence to the prednisone taper from Week 12 through Week 24.

Secondary Outcome Measures :

Number of Participants With Achievement of Disease Remission up to Week 12: Week 52 Analysis Set [ Time Frame: Up to Week 12 ]
Disease remission was defined as resolution of signs and symptoms of GCA, and normalization of CRP (< 10 mg/L). The status of normalization of CRP (<10 mg/L) was determined based on the last two non-missing post-baseline CRP values measured up to Week 12. If at least one of the value was <10 mg/L, then it was considered as normalization of CRP. Participants who took rescue corticosteroid (CS) due to active GCA prior to Week 12 or who permanently withdrew from the study treatment prior to Week 12 were considered as not achieved disease remission by Week 12.
Number of Participants With Achievement of Disease Remission up to Week 12: Intent-to-treat (ITT) Population [ Time Frame: Up to Week 12 ]
Disease remission was defined as resolution of signs and symptoms of GCA, and normalization of CRP (< 10 mg/L). The status of normalization of CRP (<10 mg/L) was determined based on the last two non-missing post-baseline CRP values measured up to Week 12. If at least one of the value was <10 mg/L, then it was considered as normalization of CRP. Participants who took rescue CS due to active GCA prior to Week 12 or who permanently withdrew from the study treatment prior to Week 12 were considered as not achieved disease remission by Week 12.
Number of Participants With Absence of Disease Flare From Week 12 Through Week 52: Week 52 Analysis Set [ Time Frame: From Week 12 through Week 52 ]
Disease flare was defined as either recurrence of signs and symptoms attributable to active GCA plus an increase in CS dose due to GCA, or elevation of ESR attributable to active GCA plus an increase in CS dose due to GCA. Number of participants with absence of disease flare from Week 12 through Week 52 were reported.
Number of Participants With Absence of Disease Flare From Week 12 Through Week 24: ITT Population [ Time Frame: From Week 12 through Week 24 ]
Disease flare was defined as either recurrence of signs and symptoms attributable to active GCA plus an increase in CS dose due to GCA, or elevation of ESR attributable to active GCA plus an increase in CS dose due to GCA. Number of participants with absence of disease flare from Week 12 through Week 24 were reported.
Number of Participants With Normalization of C-Reactive Protein From Week 12 Through Week 52: Week 52 Analysis Set [ Time Frame: From Week 12 through Week 52 ]
Normalization of CRP was defined as CRP levels <10 mg/L. If there were two or more consecutive visits with CRP >=10 mg/L, then it was categorized as no normalization of CRP.
Number of Participants With Normalization of C-Reactive Protein (CRP) From Week 12 Through Week 24: ITT Population [ Time Frame: From Week 12 through Week 24 ]
Normalization of CRP was defined as CRP levels <10 mg/L. If there were two or more consecutive visits with CRP >=10 mg/L, then it was categorized as no normalization of CRP.
Number of Participants With Successful Adherence to the Prednisone Taper From Week 12 Through Week 52: Week 52 Analysis Set [ Time Frame: From Week 12 through Week 52 ]
Successful adherence to the prednisone taper from Week 12 through Week 52 was defined as participants who did not take rescue therapy from Week 12 through Week 52 and might include the use of any excess prednisone (beyond the per protocol CS tapering regimen) with a cumulative dose of <=100 mg (or equivalent), such as those employed to manage adverse event (AE) not related to GCA.
Number of Participants With Successful Adherence to the Prednisone Taper From Week 12 Through Week 24: ITT Population [ Time Frame: From Week 12 through Week 24 ]
Successful adherence to the prednisone taper from Week 12 through Week 24 was defined as participants who did not take rescue therapy from Week 12 through Week 24 and might include the use of any excess prednisone (beyond the per protocol CS tapering regimen) with a cumulative dose of <=100 mg (or equivalent), such as those employed to manage AE not related to GCA.
Total Cumulative Corticosteroid (Including Prednisone) Dose [ Time Frame: Up to Week 52 ]
Cumulative dose of CS used for GCA disease was defined as the dose taken up to the end of treatment, including expected prednisone in tapering regimen per protocol, CS used in rescue therapy and the use of commercial prednisone (an excess of <=100 mg of prednisone during the study treatment period employed to manage AE not related to GCA). The total cumulative CS dose was based on the total number of days with complete or partial intake, no imputation was done on missed tablets.
Time to First Giant Cell Arteritis Disease Flare [ Time Frame: Up to Week 52 ]
Time to first GCA flare was defined as the duration (in days) from randomization to first GCA flare after clinical remission (defined as resolution of signs and symptoms and normalization of CRP [<10 mg/L]) and up to 52 weeks. Disease flare was defined as either the recurrence of signs or symptoms attributable to active plus an increase in CS dose due to GCA or elevation of ESR attributable to active GCA plus an increase in CS dose due to GCA. Kaplan-Meier method was used for the analysis. Participants who never achieved remission were censored at randomization day; and those who achieved clinical remission and never flared were censored at the end of treatment assessment date up to Week 52.
Composite Glucocorticoid Toxicity Index (C-GTI): Cumulative Worsening Score (CWS) and Aggregate Improvement Score (AIS) at Week 24: ITT Population [ Time Frame: At Week 24 ]
GTI assessed glucocorticoid (GC) related morbidity and GC-sparing ability of other therapies; composed of 2 components: Composite GTI and Specific List. Composite GTI contained 9 domains and Specific List contained of 23 items (11 domains), used as complementary tool to C-GTI. Composite GTI score was the sum of 9 domain-specific scores at each visit and Cumulative GTI score was the sum of composite GTI scores across each visit. Two cumulative GTI scores: CWS and AIS at Week 24 are reported in this outcome measure (OM). CWS assessed cumulative GC toxicity regardless of whether toxicity had lasting effects or was transient. AIS assessed new therapy effectiveness in decreasing any Baseline GC toxicity over time. For CWS, composite score ranged from 0 to 439 and for AIS, composite score ranged from -346 to 439. For both CWS and AIS, the minimum score implies the least toxicity and the maximum score implies the most toxicity.
Composite Glucocorticoid Toxicity Index: Cumulative Worsening Score and Aggregate Improvement Score at Week 52 [ Time Frame: At Week 52 ]
GTI assessed glucocorticoid (GC) related morbidity and GC-sparing ability of other therapies; composed of 2 components: Composite GTI and Specific List. Composite GTI contained 9 domains and Specific List contained of 23 items (11 domains), used as complementary tool to C-GTI. Composite GTI score was the sum of 9 domain-specific scores at each visit and Cumulative GTI score was the sum of composite GTI scores across each visit. Two cumulative GTI scores: CWS and AIS at Week 52 are reported in this OM. CWS assessed cumulative GC toxicity regardless of whether toxicity had lasting effects or was transient. AIS assessed new therapy effectiveness in decreasing any Baseline GC toxicity over time. For CWS, composite score ranged from 0 to 439 and for AIS, composite score ranged from -346 to 439. For both CWS and AIS, the minimum score implies the least toxicity and the maximum score implies the most toxicity.
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) [ Time Frame: From first dose (i.e., Day 1) up to 60 days after last dose (i.e., up to Week 60) ]
An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily had to have a causal relationship with the treatment. Serious AEs (SAEs) were any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. TEAEs were the AEs that developed or worsened or became serious during the TEAE period (defined as the time from the first dose of the investigational medicinal product (IMP) to the last dose of the SC IMP +60 days).
Pharmacokinetics (PK): Serum Trough Concentration (Ctrough) of Sarilumab [ Time Frame: Pre-dose on Week 0 (Baseline), Weeks 2, 4, 12, 16, 24 and 52 ]
Ctrough was pre dose concentration of drug. Data for this outcome measure was not planned to be collected and analyzed for placebo arms (Placebo+52 Week Taper and Placebo+26 Week Taper) as pre-specified in the protocol.
Pharmacokinetics: Serum Drug Concentration of Sarilumab Post-dose at Week 24 [ Time Frame: post-dose at Week 24 ]
Serum concentrations of functional sarilumab were analyzed using validated enzyme linked immunosorbent assay.
Percentage of Participants With Treatment-emergent Antidrug Antibodies (ADA) Response [ Time Frame: From Day 1 (Baseline) up to last dose date of study drug + 60 days (i.e., up to Week 60) ]
ADA response categories: 1) Treatment-boosted ADA positive participant: Participant with a positive ADA assay response at Baseline and with at least a 4-fold increase in titer compared to Baseline during TEAE period. 2) Treatment-emergent ADA positive participant: Participant with non-positive assay (meaning negative or missing) response at Baseline but with a positive assay response during the TEAE period (defined as the time from the first dose of the IMP to the last dose of the SC IMP + 60 days). Titer values were categorized as low (titer <1,000); moderate (1,000<= titer <=10,000) and high (titer >10,000).
Pharmacodynamics: Change From Baseline in Erythrocyte Sedimentation Rate (ESR) at Weeks 2, 4, 8, 12, 16, 20, 24, 32, 40, and 52 [ Time Frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 32, 40, and 52 ]
ESR is a laboratory test to provide non-specific measure of inflammation in the body. The test assessed the rate at which red blood cells fell in a test tube and was measured in millimeters per hour.
Pharmacodynamics: Change From Baseline in C-reactive Protein (CRP) Level at Weeks 2, 4, 8, 12, 16, 20, 24, 32, 40, and 52 [ Time Frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 32, 40, and 52 ]
CRP is a protein made by the liver. CRP levels increase in blood when inflammation occurs in the body.
Pharmacodynamics: Change From Baseline in Interleukin-6 (IL-6) at Weeks 2, 12, 24, and 52 [ Time Frame: Baseline, Weeks 2, 12, 24, and 52 ]
Interleukin-6 is a protein produced in the body. Levels of IL-6 often increase when there is inflammation (redness, warmth, swelling, and pain as a result of infection, irritation, or injury), either acute or chronic.
Pharmacodynamics: Change From Baseline in Soluble Interleukin-6 Receptor (sIL-6R) Level at Weeks 2, 12, 24, and 52 [ Time Frame: Baseline, Weeks 2, 12, 24, and 52 ]
Interleukin-6 is a protein produced in the body. Levels of IL-6 often increase when there is inflammation (redness, warmth, swelling, and pain as a result of infection, irritation, or injury), either acute or chronic. sIL-6R is one of the receptors that bind IL-6.

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	50 Years and older (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion criteria :

Diagnosis of GCA according to European League Against Rheumatism/American College of Rheumatology classification criteria.
New onset active disease or refractory active disease.
At least one of the symptoms of GCA within 6 weeks of baseline.
Either erythrocyte sedimentation rate greater than or equal to (>=) 30 millimeter per hour or C-reactive protein >=10 mg per liter within 6 weeks of baseline.
Received or were able to receive prednisone 20-60 mg/day for the treatment of active GCA.

Exclusion criteria:

Organ transplantation recipient (except corneas, unless it is within 3 months prior to baseline visit).
Major ischemic event, unrelated to GCA, within 12 weeks of screening.
Any prior use of the following therapies, for the treatment of GCA:
Janus kinase inhibitor (e.g., tofacitinib) within 4 weeks of baseline.
Cell-depletion agents (e.g., anti CD20) without evidence of recovery of B cells to baseline level.
Abatacept within 8 weeks of baseline.
Anakinra within 1 week of baseline.
Tumor necrosis factor inhibitors within 2-8 weeks (etanercept within 2 weeks; infliximab, certolizumab, golimumab, or adalimumab within 8 weeks), or less than at least 5 half-lives had elapsed prior to baseline, whichever was longer.
Therapeutic failure, including inadequate response or intolerance, or contraindication, to biological Interleukin 6 (IL-6) IL-6/(R) antagonist (prior experience with IL-6/(R) antagonist that was terminated for reasons unrelated to therapeutic failure at least 3 months before baseline was not exclusionary).
Use of any alkylating agents including cyclophosphamide within 6 months of baseline.
Use of immunosuppressant, such as hydroxychloroquine, cyclosporine, azathioprine, mycophenolate mofetil or leflunomide within 4 weeks of baseline. (Use of methotrexate (MTX) not exceeding 25 mg per week and had been stable for at least 3 months prior to baseline was not exclusionary).
Concurrent use of systemic CS for conditions other than GCA.
Use of intervascular CS at a dose equivalent to 100 mg of methylprednisolone or higher within 8 weeks of baseline for GCA therapy.
Pregnant or breastfeeding woman.
Participants with active or untreated latent tuberculosis.
Participants with history of invasive opportunistic infections.
Participants with fever associated with infection or chronic, persistent or recurring infections requiring active treatment.
Participants with uncontrolled diabetes mellitus.
Participants with non-healed or healing skin ulcers.
Participants who received any live, attenuated vaccine within 3 months of baseline.
Participants who are positive for hepatitis B, hepatitis C and/or HIV.
Participants with a history of active or recurrent herpes zoster.
Participants with a history of or prior articular or prosthetic joint infection.
Prior or current history of malignancy.
Participants who have had surgery within 4 weeks of screening or planned surgery during study.
Participants with a history of inflammatory bowel disease or severe diverticulitis or previous gastrointestinal perforation..

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03600805

Locations

Show 61 study locations

Layout table for location information

United States, Florida
Investigational Site Number 8400002
Boca Raton, Florida, United States, 33486
Investigational Site Number 8400017
Gainesville, Florida, United States, 32608
United States, Iowa
Investigational Site Number 8400014
Iowa City, Iowa, United States, 52242
United States, Oregon
Investigational Site Number 8400018
Portland, Oregon, United States, 97239
United States, Pennsylvania
Investigational Site Number 8400019
Philadelphia, Pennsylvania, United States, 19104
United States, Texas
Investigational Site Number 8400011
Dallas, Texas, United States, 75231
Argentina
Investigational Site Number 0320001
Buenos Aires, Argentina, C1015ABO
Investigational Site Number 0320002
Caba, Argentina, C1181ACH
Australia
Investigational Site Number 0360003
Camberwell, Australia, 3124
Investigational Site Number 0360006
Clayton, Australia, 3168
Investigational Site Number 0360001
Kogarah, Australia, 2217
Belgium
Investigational Site Number 0560001
Leuven, Belgium, 3000
Canada
Investigational Site Number 1240007
Hamilton, Canada, L8N 4A6
Investigational Site Number 1240010
Montreal, Canada, H4A 3T2
Investigational Site Number 1240001
Rimouski, Canada, G5L 5T1
Investigational Site Number 1240005
Sherbrooke, Canada, J1G 2E8
Investigational Site Number 1240003
Trois-Rivières, Canada, G8Z 1Y2
Croatia
Investigational Site Number 1910001
Zagreb, Croatia, 10000
Denmark
Investigational Site Number 2080002
Aarhus C, Denmark, 8000
Investigational Site Number 2080003
Svendborg, Denmark, 5700
Estonia
Investigational Site Number 2330001
Tallinn, Estonia, 13419
France
Investigational Site Number 2500005
Brest Cedex, France, 29609
Investigational Site Number 2500002
Montivilliers, France, 76290
Investigational Site Number 2500003
Montpellier, France, 34295
Investigational Site Number 2500007
Mulhouse, France, 68100
Investigational Site Number 2500001
Paris, France, 75014
Investigational Site Number 2500006
Pessac, France, 33604
Germany
Investigational Site Number 2760001
Berlin, Germany, 13125
Investigational Site Number 2760002
Dresden, Germany, 01307
Investigational Site Number 2760003
Kirchheim Unter Teck, Germany, 73230
Investigational Site Number 2760004
München, Germany, 80336
Investigational Site Number 2760007
Tübingen, Germany, 72076
Hungary
Investigational Site Number 3480001
Debrecen, Hungary, 4032
Israel
Investigational Site Number 3760006
Ashkelon, Israel, 78278
Investigational Site Number 3760004
Haifa, Israel, 34362
Italy
Investigational Site Number 3800001
Milano, Italy, 20132
Investigational Site Number 3800005
Rozzano, Italy, 20089
Netherlands
Investigational Site Number 5280007
Den Haag, Netherlands, 2545 CH
Investigational Site Number 5280005
Leeuwarden, Netherlands, 8934 AD
Investigational Site Number 5280009
Sittard-Geleen, Netherlands, 6162 BG
Investigational Site Number 5280001
Venlo, Netherlands, 5912 BL
Portugal
Investigational Site Number 6200001
Almada, Portugal, 2801-951
Investigational Site Number 6200005
Aveiro, Portugal, 3810-501
Investigational Site Number 6200004
Ponte De Lima, Portugal, 4990-041
Russian Federation
Investigational Site Number 6430005
Kemerovo, Russian Federation, 650000
Investigational Site Number 6430002
Moscow, Russian Federation, 115404
Investigational Site Number 6430003
Moscow, Russian Federation, 123182
Slovenia
Investigational Site Number 7050001
Ljubljana, Slovenia, 1000
Spain
Investigational Site Number 7240010
Bilbao, Spain, 48013
Investigational Site Number 7240011
La Coruña, Spain, 15006
Investigational Site Number 7240014
Madrid, Spain, 28046
Investigational Site Number 7240016
Sabadell, Spain, 08208
Investigational Site Number 7240015
Santa Cruz De Tenerife, Spain, 38320
Sweden
Investigational Site Number 7520001
Uppsala, Sweden, 751 85
Investigational Site Number 7520003
Örebro, Sweden, 701 85
Switzerland
Investigational Site Number 7560002
St. Gallen, Switzerland, 9007
United Kingdom
Investigational Site Number 8260006
Aberdeen, United Kingdom, AB25 2ZN
Investigational Site Number 8260004
Gateshead, United Kingdom, NE9 6SX
Investigational Site Number 8260003
Leeds, United Kingdom, LS7 4SA
Investigational Site Number 8260005
Manchester, United Kingdom, M13 9WL
Investigational Site Number 8260011
Portsmouth, United Kingdom, PO6 3LY

Sponsors and Collaborators

Sanofi

Regeneron Pharmaceuticals

Investigators

Layout table for investigator information

Study Director:	Clinical Sciences & Operations	Sanofi

Study Documents (Full-Text)

Documents provided by Sanofi:

Study Protocol [PDF] September 12, 2018

Statistical Analysis Plan [PDF] January 8, 2021

More Information

Layout table for additonal information

Responsible Party:	Sanofi
ClinicalTrials.gov Identifier:	NCT03600805
Other Study ID Numbers:	EFC15068 2017-002988-18 ( EudraCT Number ) U1111-1200-2184 ( Other Identifier: UTN )
First Posted:	July 26, 2018 Key Record Dates
Results First Posted:	January 14, 2022
Last Update Posted:	March 28, 2022
Last Verified:	March 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD:	Yes
Plan Description:	Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

Layout table for additional information

Studies a U.S. FDA-regulated Drug Product:	Yes
Studies a U.S. FDA-regulated Device Product:	No

Additional relevant MeSH terms:

Layout table for MeSH terms

Polymyalgia Rheumatica Giant Cell Arteritis Arteritis Vasculitis Vascular Diseases Cardiovascular Diseases Vasculitis, Central Nervous System Autoimmune Diseases of the Nervous System Nervous System Diseases Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases Skin Diseases, Vascular Skin Diseases	Autoimmune Diseases Immune System Diseases Muscular Diseases Musculoskeletal Diseases Rheumatic Diseases Connective Tissue Diseases Prednisone Anti-Inflammatory Agents Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Antineoplastic Agents, Hormonal Antineoplastic Agents

To Top